NCT03679091View on ClinicalTrials.gov

Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD.

PHASE4CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

August 29, 2018

Primary Completion Date

February 28, 2019

Study Completion Date

February 28, 2019

Conditions
Platelet Reactivity
Interventions
DRUG

low-dose ticagrelor

low-dose ticagrelor (60.0 mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of clopidogrel (75mg once daily).

DRUG

Clopidogrel

clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7 days crossover phase of low-dose ticagrelor (60.0 mg once daily).

Trial Locations (1)

150001

VerifyNow, Harbin

All Listed Sponsors
lead

First Affiliated Hospital of Harbin Medical University

OTHER

NCT03679091 - Low-dose of Ticagrelor and Standard-dose Clopidogrel on Platelet Effects in Chinese Patients With Stable CAD. | Biotech Hunter | Biotech Hunter